News Equillium, Inc.

Equities

EQ

US29446K1060

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-18 pm EDT			5-day change	1st Jan Change
1.73 ^USD	-3.35%		-11.28%	+139.28%

Apr. 02	H.C. Wainwright Adjusts Price Target on Equillium to $5 From $4, Keeps Buy Rating	MT
Apr. 01	Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1B Equalise Study of Itolizumab in Lupus Nephritis	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	Apr. 03	BU
H.C. Wainwright Adjusts Price Target on Equillium to $5 From $4, Keeps Buy Rating	Apr. 02	MT
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis	Apr. 01	BU
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1B Equalise Study of Itolizumab in Lupus Nephritis	Apr. 01	CI
Health Care Climbs on Weight-Loss Drug Excitement -- Health Care Roundup	Mar. 26	DJ
Equillium Swings to Q4 Loss As Revenue Falls	Mar. 25	MT
Equillium, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
Equillium, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 25	CI
Earnings Flash (EQ) EQUILLIUM Reports Q4 Revenue $9.2M	Mar. 25	MT
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights	Mar. 25	BU
Equillium to Present at the H.C. Wainwright Autoimmune and Inflammatory Disease Conference and the LD Micro Invitational Conference	Mar. 25	AQ
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference	Mar. 22	BU
EQUILLIUM : 2024 INDUCEMENT PLAN - Form 8-K	Mar. 08	PU
HC Wainwright Adjusts Price Target on Equillium to $4 From $4.50, Keeps Buy Rating	Dec. 26	MT
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 and EQ102 in Development for Alopecia Areata and Celiac Disease	Dec. 22	AQ
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease	Dec. 21	BU
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease	Dec. 21	CI
EQ Bank Card launches in Québec as Carte Banque EQ	Nov. 20	AQ
HC Wainwright Adjusts Equillium's Price Target to $4.50 From $5.50, Maintains Buy Rating	Nov. 13	MT
Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology	Nov. 13	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Equillium, Inc.

Equities

EQ

US29446K1060

Summary

Filters